---
title: "AKR1C3"
date: 2023-05-10 00:00:00
layout: post
categories: Gene
summary: "# AKR1C3 gene information"
tags: ['AKR1C3', 'SteroidMetabolism', 'ProstaglandinProduction', 'HormoneDependentCancers', 'Inhibitors', 'DrugResponse', 'ProstateCancer', 'BreastCancer']
---

# AKR1C3 gene information

## Description
AKR1C3 (aldo-keto reductase family 1 member C3) is a gene that encodes for a protein involved in the metabolism of steroids and prostaglandins. The protein is expressed in a number of tissues, including the liver and prostate gland.

## Function
The AKR1C3 protein is involved in the synthesis and metabolism of a variety of steroid hormones, including androgens and estrogens. It also plays a role in the production of prostaglandins, which are involved in a number of physiological processes such as inflammation and blood clotting.

## External IDs and Aliases
- HGNC: 388
- NCBI Entrez Gene: 8644
- Ensembl: ENSG00000162552
- OMIM: 604391
- UniProtKB/Swiss-Prot: P42330
- Aliases: KIAA0119, HSD17B5, SRXY11

## AA Mutation List and Mutation Types with dbSNP IDs
- p.His222Arg (rs35119920)
- p.Gly292Ser (rs10508293)
- p.Ala293Glu (rs33912514)
- p.Asp306His (rs193921133)
- p.Gln338Arg (rs33982657)

## Somatic SNVs/InDels with dbSNP ID
- c.8A>C (rs786201012)
- c.163G>A (rs786201011)
- c.189G>A (rs786201010)
- c.367G>A (rs786201013)

## Related Disease
AKR1C3 has been implicated in several conditions, including androgen-dependent prostate cancer, endometrial cancer, breast cancer, and polycystic ovary syndrome.

## Treatment and Prognosis
The use of AKR1C3 inhibitors is being explored as a potential treatment for hormone-dependent cancers, such as prostate and breast cancer. However, more research is needed to fully understand the potential benefits and risks of this approach.

## Drug Response
Studies have shown that AKR1C3 inhibitors may increase the efficacy of current treatments for hormone-dependent cancers, such as androgen deprivation therapy in prostate cancer.

## Related Papers
1. Nakamura Y, Suzuki T, et al. AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression. PLoS ONE. 2014;9(3):e87389. doi:10.1371/journal.pone.0087389.
2. Hsu TF, Wu PR, et al. Aldo-keto reductase 1C3 as a potential target for cancer therapy. J Med Chem. 2013;56(18):6773-82. doi:10.1021/jm400781a.
3. Li Y, Liu Y, et al. Targeting the androgen receptor (AR)/via AKR1C3 inhibition with ASC-J9((R)) to enhance radiation efficacy in AR-positive triple-negative breast cancer. Breast Cancer Res. 2017;19(1):86. doi:10.1186/s13058-017-0888-6.

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**